Stockreport

Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Vaccinex, Inc.  (VCNX) 
PDF Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 U [Read more]